Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II / Christopher H. CHATHAM in Autism Research, 11-2 (February 2018)  

Public ISBD [article]  inAutism Research > 11-2 (February 2018) . - p.270-283 Titre : Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II Type de document : texte imprimé Auteurs : Christopher H. CHATHAM, Auteur ; K.I. TAYLOR, Auteur ; Tony CHARMAN, Auteur ; X. Liogier D'ARDHUY, Auteur ; E. EULE, Auteur ; A. FEDELE, Auteur ; Antonio Y. HARDAN, Auteur ; Eva LOTH, Auteur ; Lorraine MURTAGH, Auteur ; Marta DEL VALLE RUBIDO, Auteur ; Antonia SAN JOSE CACERES, Auteur ; J. SEVIGNY, Auteur ; Linmarie SIKICH, Auteur ; L. SNYDER, Auteur ; J.E. TILLMANN, Auteur ; Pamela VENTOLA, Auteur ; Karen WALTON-BOWEN, Auteur ; P.P. WANG, Auteur ; Tom WILLGOSS, Auteur ; Federico BOLOGNANI, Auteur Année de publication : 2018 Article en page(s) : p.270-283 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland‐II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland‐II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU‐AIMS LEAP study, ABIDE‐I, ABIDE‐II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution‐based methods and anchor‐based methods. Distribution‐based MCID [d‐MCID] estimates included the standard error of the measurement, as well as one‐fifth and one‐half of the covariate‐adjusted standard deviation (both cross‐sectionally and longitudinally). Anchor‐based MCID [a‐MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland‐II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland‐II change, the Vineland‐II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland‐II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution‐based methods, and from 2.42 to 3.75 for sample‐size‐weighted anchor‐based methods. Lower Vineland‐II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland‐II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270–283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary The Vineland Adaptive Behavior Scales (2nd edition; Vineland‐II) is the most widely used scale for assessing day‐to‐day “adaptive” skills. Yet, it is unknown how much Vineland‐II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2–3.75 points on the Vineland‐II Composite score represent the “minimal clinically‐important difference.” These estimates will help evaluate the benefits of potential new treatments for ASD. En ligne : https://doi.org/10.1002/aur.1874 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=334 [article] Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II [texte imprimé] / Christopher H. CHATHAM, Auteur ; K.I. TAYLOR, Auteur ; Tony CHARMAN, Auteur ; X. Liogier D'ARDHUY, Auteur ; E. EULE, Auteur ; A. FEDELE, Auteur ; Antonio Y. HARDAN, Auteur ; Eva LOTH, Auteur ; Lorraine MURTAGH, Auteur ; Marta DEL VALLE RUBIDO, Auteur ; Antonia SAN JOSE CACERES, Auteur ; J. SEVIGNY, Auteur ; Linmarie SIKICH, Auteur ; L. SNYDER, Auteur ; J.E. TILLMANN, Auteur ; Pamela VENTOLA, Auteur ; Karen WALTON-BOWEN, Auteur ; P.P. WANG, Auteur ; Tom WILLGOSS, Auteur ; Federico BOLOGNANI, Auteur . - 2018 . - p.270-283. Langues : Anglais (eng) in Autism Research > 11-2 (February 2018) . - p.270-283 Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland‐II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland‐II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU‐AIMS LEAP study, ABIDE‐I, ABIDE‐II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution‐based methods and anchor‐based methods. Distribution‐based MCID [d‐MCID] estimates included the standard error of the measurement, as well as one‐fifth and one‐half of the covariate‐adjusted standard deviation (both cross‐sectionally and longitudinally). Anchor‐based MCID [a‐MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland‐II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland‐II change, the Vineland‐II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland‐II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution‐based methods, and from 2.42 to 3.75 for sample‐size‐weighted anchor‐based methods. Lower Vineland‐II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland‐II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270–283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary The Vineland Adaptive Behavior Scales (2nd edition; Vineland‐II) is the most widely used scale for assessing day‐to‐day “adaptive” skills. Yet, it is unknown how much Vineland‐II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2–3.75 points on the Vineland‐II Composite score represent the “minimal clinically‐important difference.” These estimates will help evaluate the benefits of potential new treatments for ASD. En ligne : https://doi.org/10.1002/aur.1874 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=334

Correction to: Exploring Social Biomarkers in HighFunctioning Adults with Autism and Asperger's Versus Healthy Controls: A CrossSectional Analysis / Marta DEL VALLE RUBIDO in Journal of Autism and Developmental Disorders, 50-12 (December 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-12 (December 2020) . - p.4431-4432 Titre : Correction to: Exploring Social Biomarkers in HighFunctioning Adults with Autism and Asperger's Versus Healthy Controls: A CrossSectional Analysis Type de document : texte imprimé Auteurs : Marta DEL VALLE RUBIDO, Auteur ; Eric HOLLANDER, Auteur ; James T. MCCRACKEN, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur Article en page(s) : p.4431-4432 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The original version of this article unfortunately contained a mistake in CI values in Table 2. En ligne : http://dx.doi.org/10.1007/s10803-020-04522-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=434 [article] Correction to: Exploring Social Biomarkers in HighFunctioning Adults with Autism and Asperger's Versus Healthy Controls: A CrossSectional Analysis [texte imprimé] / Marta DEL VALLE RUBIDO, Auteur ; Eric HOLLANDER, Auteur ; James T. MCCRACKEN, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur . - p.4431-4432. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-12 (December 2020) . - p.4431-4432 Index. décimale : PER Périodiques Résumé : The original version of this article unfortunately contained a mistake in CI values in Table 2. En ligne : http://dx.doi.org/10.1007/s10803-020-04522-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=434

Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis / Marta DEL VALLE RUBIDO in Journal of Autism and Developmental Disorders, 50-12 (December 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-12 (December 2020) . - p.4412-4430 Titre : Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis Type de document : texte imprimé Auteurs : Marta DEL VALLE RUBIDO, Auteur ; Eric HOLLANDER, Auteur ; James T. MCCRACKEN, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur Article en page(s) : p.4412-4430 Langues : Anglais (eng) Mots-clés : Biomarker  Eye movement  Olfactory  Social cognition  Curemark, Coronado Biosciences, Forest, Simons Foundation, Foundation for Prader  Willi Research, and the Orphan Products Division of the Food and Drug  Administration, and has intellectual property relating to oxytocin and autism. FS  has provided consultation to Roche and Janssen Pharmaceutical and has received  research grants from Roche, NIH, and the Simons Foundation. JTM has served as a  consultant for Roche and Dart Neuroscience, has received research grants from Roche,  and has received study drug from Shire and AstraZeneca. FS has received research  funding from Roche and Janssen Pharmaceuticals. MVR, DU, JN, LB, OK, SS and PF are  full-time employees of F. Hoffmann-La Roche. Index. décimale : PER Périodiques Résumé : Biomarkers for autism spectrum disorder (ASD) are lacking but would facilitate drug development for the core deficits of the disorder. We evaluated markers proposed for characterization of differences in social communication and interaction in adults with ASD versus healthy controls (HC) for utility as biomarkers. Data pooled from an observational study and baseline data from a placebo-controlled study were analyzed. Between-group differences were observed in eye-tracking tasks for activity monitoring, biomotion, human activity preference, composite score (p = 0.0001-0.037) and pupillometry (various tasks, p = 0.017-0.05). Impaired olfaction was more common in the ASD sample versus HC (p = 0.018). Our preliminary results suggest the potential use for stratification and response sub-analyses outcome-prediction of specific eye-tracking tasks, pupillometry and olfaction tests in ASD trials. En ligne : http://dx.doi.org/10.1007/s10803-020-04493-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=434 [article] Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis [texte imprimé] / Marta DEL VALLE RUBIDO, Auteur ; Eric HOLLANDER, Auteur ; James T. MCCRACKEN, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur . - p.4412-4430. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-12 (December 2020) . - p.4412-4430 Mots-clés : Biomarker  Eye movement  Olfactory  Social cognition  Curemark, Coronado Biosciences, Forest, Simons Foundation, Foundation for Prader  Willi Research, and the Orphan Products Division of the Food and Drug  Administration, and has intellectual property relating to oxytocin and autism. FS  has provided consultation to Roche and Janssen Pharmaceutical and has received  research grants from Roche, NIH, and the Simons Foundation. JTM has served as a  consultant for Roche and Dart Neuroscience, has received research grants from Roche,  and has received study drug from Shire and AstraZeneca. FS has received research  funding from Roche and Janssen Pharmaceuticals. MVR, DU, JN, LB, OK, SS and PF are  full-time employees of F. Hoffmann-La Roche. Index. décimale : PER Périodiques Résumé : Biomarkers for autism spectrum disorder (ASD) are lacking but would facilitate drug development for the core deficits of the disorder. We evaluated markers proposed for characterization of differences in social communication and interaction in adults with ASD versus healthy controls (HC) for utility as biomarkers. Data pooled from an observational study and baseline data from a placebo-controlled study were analyzed. Between-group differences were observed in eye-tracking tasks for activity monitoring, biomotion, human activity preference, composite score (p = 0.0001-0.037) and pupillometry (various tasks, p = 0.017-0.05). Impaired olfaction was more common in the ASD sample versus HC (p = 0.018). Our preliminary results suggest the potential use for stratification and response sub-analyses outcome-prediction of specific eye-tracking tasks, pupillometry and olfaction tests in ASD trials. En ligne : http://dx.doi.org/10.1007/s10803-020-04493-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=434

In Search of Biomarkers for Autism Spectrum Disorder / Marta DEL VALLE RUBIDO in Autism Research, 11-11 (November 2018)  

Public ISBD [article]  inAutism Research > 11-11 (November 2018) . - p.1567-1579 Titre : In Search of Biomarkers for Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Marta DEL VALLE RUBIDO, Auteur ; James T. MCCRACKEN, Auteur ; Eric HOLLANDER, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur Article en page(s) : p.1567-1579 Langues : Anglais (eng) Mots-clés : biomarker  eye movement  olfactory  social cognition Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) lacks validated measures of core social functions across development stages suitable for clinical trials. We assessed the concurrent validity between ASD clinical measures and putative biomarkers of core deficits, and their feasibility of implementation in human studies. Datasets from two adult ASD studies were combined (observational study [n = 19] and interventional study baseline data [n = 19]). Potential biomarkers included eye-tracking, olfaction, and auditory and visual emotion recognition assessed via the Affective Speech Recognition test (ASR) and Reading-the-Mind-in-the-Eyes Test (RMET). Current functioning was assessed with intelligence quotient (IQ), adaptive skill testing, and behavioral ratings. Autism severity was determined by the Autism Diagnostic Observation Scale-2 and Social Communication Interaction Test (SCIT). Exploratory measures showed varying significant associations across ASD severity, adaptive skills, and behavior. Eye tracking endpoints showed little relationship to adaptive ability but correlated with severity and behavior. ASR scores significantly correlated with most adaptive behavior domains, as well as severity. Olfaction predicted visual and auditory emotion recognition. SCIT scores related moderately to multiple severity domains, and was the only measure not related with IQ. RMET accuracy was less related to ASD features. Eye tracking, SCIT, and ASR showed high test-retest reliability. We documented associations of proximal biomarkers of social functioning with multiple ASD dimensions. With the exception of SCIT, most correlations were modest, limiting utility as proxy measures of social communication. Feasibility and reliability were high for eye-tracking, ASR, and SCIT. Overall, several novel experimental paradigms showed potential as social biomarkers or surrogate markers in ASD. Autism Research 2018, 11: 1567-1579. (c) 2018 The Authors. Autism Research published by International Society for Autism Research and Wiley Periodicals, Inc. LAY SUMMARY: More accurate measurements of treatment effects are needed to help the development of new drug treatments for autism spectrum disorders (ASD). This study evaluates the relationship between assessments designed to measure behaviors associated with social communication and cognition in ASD with clinical and diagnostic assessments of symptom severity as well as their implementation. The assessments including eye-tracking, auditory and visual social stimuli recognition, and olfaction identification showed potential for use in the evaluation of treatments for social difficulties in ASD. En ligne : http://dx.doi.org/10.1002/aur.2026 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370 [article] In Search of Biomarkers for Autism Spectrum Disorder [texte imprimé] / Marta DEL VALLE RUBIDO, Auteur ; James T. MCCRACKEN, Auteur ; Eric HOLLANDER, Auteur ; Frederick SHIC, Auteur ; Jana NOELDEKE, Auteur ; Lauren BOAK, Auteur ; Omar KHWAJA, Auteur ; Shamil SADIKHOV, Auteur ; Paulo FONTOURA, Auteur ; Daniel UMBRICHT, Auteur . - p.1567-1579. Langues : Anglais (eng) in Autism Research > 11-11 (November 2018) . - p.1567-1579 Mots-clés : biomarker  eye movement  olfactory  social cognition Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorder (ASD) lacks validated measures of core social functions across development stages suitable for clinical trials. We assessed the concurrent validity between ASD clinical measures and putative biomarkers of core deficits, and their feasibility of implementation in human studies. Datasets from two adult ASD studies were combined (observational study [n = 19] and interventional study baseline data [n = 19]). Potential biomarkers included eye-tracking, olfaction, and auditory and visual emotion recognition assessed via the Affective Speech Recognition test (ASR) and Reading-the-Mind-in-the-Eyes Test (RMET). Current functioning was assessed with intelligence quotient (IQ), adaptive skill testing, and behavioral ratings. Autism severity was determined by the Autism Diagnostic Observation Scale-2 and Social Communication Interaction Test (SCIT). Exploratory measures showed varying significant associations across ASD severity, adaptive skills, and behavior. Eye tracking endpoints showed little relationship to adaptive ability but correlated with severity and behavior. ASR scores significantly correlated with most adaptive behavior domains, as well as severity. Olfaction predicted visual and auditory emotion recognition. SCIT scores related moderately to multiple severity domains, and was the only measure not related with IQ. RMET accuracy was less related to ASD features. Eye tracking, SCIT, and ASR showed high test-retest reliability. We documented associations of proximal biomarkers of social functioning with multiple ASD dimensions. With the exception of SCIT, most correlations were modest, limiting utility as proxy measures of social communication. Feasibility and reliability were high for eye-tracking, ASR, and SCIT. Overall, several novel experimental paradigms showed potential as social biomarkers or surrogate markers in ASD. Autism Research 2018, 11: 1567-1579. (c) 2018 The Authors. Autism Research published by International Society for Autism Research and Wiley Periodicals, Inc. LAY SUMMARY: More accurate measurements of treatment effects are needed to help the development of new drug treatments for autism spectrum disorders (ASD). This study evaluates the relationship between assessments designed to measure behaviors associated with social communication and cognition in ASD with clinical and diagnostic assessments of symptom severity as well as their implementation. The assessments including eye-tracking, auditory and visual social stimuli recognition, and olfaction identification showed potential for use in the evaluation of treatments for social difficulties in ASD. En ligne : http://dx.doi.org/10.1002/aur.2026 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370

---

1 (1 - 4 / 4) Par page : 25 50 100 200